Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosmanogepix DDI and QTc Study in Healthy Adults
NCT07881224Phase 1Recruiting
- Sponsor
- Basilea Pharmaceutica
- Start
- Oct 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1 trial of fosmanogepix in fungal infection (2 arms), sponsored by Basilea Pharmaceutica. Primary endpoints: Maximum Plasma Concentration at Day 22 and Area Under the Concentration-Time Curve at Day 22. Started Oct 2026; status: recruiting.
02
Drugs
fosmanogepix
03
Conditions
fungal infection
Beyond the preview
Go deeper on NCT07881224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07881224.